CTCX 📈 Carmell Therapeutics - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock •

CTCX: Skin Care, Hair Care, Men's Grooming Products, Plasma-Based Plastics

Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania. Web URL: https://www.carmellcosmetics.com

Additional Sources for CTCX Stock

CTCX Stock Overview

Market Cap in USD 7m
Sector Consumer Defensive
Industry Household & Personal Products
GiC Sub-Industry Biotechnology
IPO / Inception 2023-07-17

CTCX Stock Ratings

Growth 5y -84.3%
Fundamental 7.95%
Dividend -
Rel. Strength Industry -6952
Analysts -
Fair Price Momentum 0.32 USD
Fair Price DCF -

CTCX Dividends

No Dividends Paid

CTCX Growth Ratios

Growth Correlation 3m -34.9%
Growth Correlation 12m -96.1%
Growth Correlation 5y -68.7%
CAGR 5y -61.45%
CAGR/Mean DD 5y -1.68
Sharpe Ratio 12m -0.27
Alpha -102.97
Beta 0.44
Volatility 646.08%
Current Volume 482.6k
Average Volume 20d 20019.4k
What is the price of CTCX stocks?
As of January 10, 2025, the stock is trading at USD 0.42 with a total of 482,570 shares traded.
Over the past week, the price has changed by -39.30%, over one month by +51.06%, over three months by -2.05% and over the past year by -87.27%.
Is Carmell Therapeutics a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Carmell Therapeutics is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 7.95 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CTCX as of January 2025 is 0.32. This means that CTCX is currently overvalued and has a potential downside of -23.81%.
Is CTCX a buy, sell or hold?
Carmell Therapeutics has no consensus analysts rating.
What are the forecast for CTCX stock price target?
According to ValueRays Forecast Model, CTCX Carmell Therapeutics will be worth about 0.3 in January 2026. The stock is currently trading at 0.42. This means that the stock has a potential downside of -19.05%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 0.3 -19%